N
Neill Iscoe
Researcher at Eli Lilly and Company
Publications - 25
Citations - 980
Neill Iscoe is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Pemetrexed & Lung cancer. The author has an hindex of 12, co-authored 24 publications receiving 873 citations. Previous affiliations of Neill Iscoe include University of Toronto & Sunnybrook Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Suresh Senan,Anthony Brade,Lu Hua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Belen San Antonio,Nadia Chouaki,Everett E. Vokes +20 more
TL;DR: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.
Journal ArticleDOI
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
TL;DR: No systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high‐risk, resected, primary melanoma, but high‐dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease‐free survival and a reduction in 2‐year mortality.
Journal Article
Variation in breast cancer surgery in Ontario
TL;DR: There was marked variation at the hospital and county level in the use of breast-conserving surgery in the initial management of breast cancer and this variation was strongly associated with the hospital where the surgery was performed.
Journal ArticleDOI
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
M. H. Cullen,Petr Zatloukal,Sverre Sörenson,Silvia Novello,J. R. Fischer,Anil A. Joy,M. Zereu,Patrick Peterson,Carla Visseren-Grul,Neill Iscoe +9 more
TL;DR: P500 i.v. every 3 week remains the standard pemetrexed dose for second-line treatment of platinum-pretreated advanced NSCLC and P900 did not improve any efficacy measure over P500.
Journal ArticleDOI
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology.
TL;DR: This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation peterrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer.